Skip to main content
欧康医药 logo

欧康医药 — Investor Relations & Filings

Ticker · 920230 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 373 across all filing types
Latest filing 2023-06-08 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920230

About 欧康医药

https://www.okaypharm.com/

Oukang Pharmaceutical specializes in the research, development, and large-scale production of natural plant extracts, with a primary focus on citrus-derived flavonoids. The company’s core product portfolio includes high-purity ingredients such as Hesperidin, Diosmin, Methyl Hesperidin, and Neohesperidin Dihydrochalcone (NHDC). These products serve as essential raw materials for the global pharmaceutical, nutraceutical, food and beverage, and cosmetic sectors. Utilizing advanced extraction and purification technologies, the company maintains rigorous quality control standards to ensure compliance with international regulatory requirements. Its operations emphasize the industrialization of plant-based chemical derivatives to support diverse health and wellness applications.

Recent filings

Filing Released Lang Actions
关于全资子公司变更经营范围并完成工商变更登记的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the change in business scope of a wholly-owned subsidiary of the company and the completion of the related industrial and commercial registration. It contains no financial data, no discussion of financial results, no regulatory certifications, or voting results. It is a corporate announcement about operational changes at a subsidiary level. The document length is short (1328 characters) and it is not a report or a presentation. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not about board or management changes, nor about shareholding or capital changes. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous corporate announcements that do not fit other categories.
2023-06-08 Chinese
关于取得发明专利证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Chengdu Oukang Pharmaceutical Co., Ltd. regarding the receipt of two invention patent certificates issued by the National Intellectual Property Office. It details the patent numbers, invention names, and the significance of these patents to the company. There is no financial data, no mention of financial results, no regulatory filings related to financial performance, no management or board changes, no voting results, no capital or financing updates, and no legal proceedings. The document is an announcement of a patent grant, which is a regulatory announcement but does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a report publication announcement since it is not about a report. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2023-05-29 Chinese
2022年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is titled as an announcement regarding the implementation of the 2022 annual equity distribution (dividend) by Chengdu Oukang Pharmaceutical Co., Ltd. It details the dividend amount, payment dates, tax treatment, and record dates. The document is short (1200 characters) and focuses on dividend distribution specifics rather than full financial results or reports. It is not a full annual report or earnings release but a formal announcement of dividend payment details. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2023-05-14 Chinese
2022年度权益分派预案公告（更正公告）
Notice of Dividend Amount Classification · 95% confidence The document is a correction announcement related to a previously disclosed 2022 annual equity distribution plan (权益分派预案). It references the 2022 annual report and audited financials but does not contain the full annual report itself. The document is short (1149 characters) and focuses on correcting specific details about profit distribution and commitments. It is an announcement about dividend distribution plans and corrections to that announcement, not the actual dividend notice or full annual report. Given the content and length, it fits best as a Notice of Dividend Amount (DIV) or a correction to such a notice. Since it specifically addresses the equity distribution plan (dividend plan) and corrections to it, the appropriate classification is Notice of Dividend Amount (DIV).
2023-05-11 Chinese
2022年度权益分派预案公告（更正后）
Notice of Dividend Amount Classification · 95% confidence The document is a detailed announcement regarding the 2022 annual profit distribution plan (权益分派预案) of Chengdu Oukang Pharmaceutical Co., Ltd. It includes specifics about dividend amounts, board and supervisory committee approvals, independent director opinions, and references to company articles of association and profit distribution policies. The document is not the full annual report but a specific announcement about the dividend distribution plan for the year 2022. It is not a simple notification of a report publication but a substantive announcement about dividend distribution details and approvals. Therefore, it fits best under the category of Notice of Dividend Amount (DIV). The document length is 2824 characters, which is consistent with a detailed dividend announcement rather than a full annual report or other types of filings.
2023-05-11 Chinese
北京德恒（重庆）律师事务所关于成都欧康医药股份有限公司2022年年度股东大会的法律意见
AGM Information Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the legality of the 2022 Annual General Meeting (AGM) of Chengdu Oukang Pharmaceutical Co., Ltd. It details the procedures of convening and holding the AGM, qualifications of attendees, proposal procedures, voting procedures, and voting results. The document does not contain financial statements or management discussion but focuses on the legal compliance and validity of the AGM process and its resolutions. This type of document is typically associated with AGM Information filings, as it supports the AGM proceedings rather than being the AGM report itself or voting results announcement. The document length is 7749 characters, which is substantial and contains detailed legal opinion rather than a brief announcement. Therefore, the most appropriate classification is AGM Information (AGM-R).
2023-05-09 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.